Study guide
13.1 Molecular Blood Group Techniques
Specialist in Blood Banking, SBB ASCP
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
1.1 Current Exam Facts 1.2 Eligibility Routes & Credential Maintenance 1.3 Study Strategy for SBB
2 Donors & Collection
2.1 Donor Qualification 2.2 Collection Methods & Adverse Reactions 2.3 Special Donations
3 Processing, Storage & Component QC
3.1 Processing, Testing & Labeling 3.2 Storage, Transport & Expiration 3.3 Blood Component Quality Control
4 Red Cell & Modified Components
4.1 Whole Blood & Red Blood Cells 4.2 Leukocyte-Reduced, Washed, Frozen & Rejuvenated RBCs 4.3 Irradiated Components 4.4 Granulocytes
5 Platelets, Plasma & Cellular Products
5.1 Platelets 5.2 Plasma & Cryoprecipitated AHF 5.3 Apheresis Products & Fractionation Products 5.4 Hematopoietic Progenitors
6 Genetics, ABO & Rh
6.1 Blood Group Genetics & Molecular Inheritance 6.2 ABO & Lewis Systems 6.3 Rh System 6.4 MNS, P1PK/Globoside & Ii
7 Other Blood Groups & Role in Transfusion
7.1 Kell, Kidd, Duffy & Lutheran 7.2 Other Systems & High/Low-Prevalence Antigens 7.3 HLA, Platelet-Specific & Granulocyte Antigens 7.4 Immunogenicity & Antigen Prevalence
8 Immunology Foundations
8.1 Immune Response 8.2 Immunoglobulins 8.3 Antigen-Antibody Interactions 8.4 Complement
9 Physiology, Hemostasis & HDFN
9.1 Physiology of Blood 9.2 Hemostasis and Coagulation 9.3 HDFN Pathophysiology & Detection 9.4 HDFN Treatment & Prevention
10 Cytopenias & Transplantation
10.1 Immune & Nonimmune Anemia 10.2 Thrombocytopenia & Neutropenia 10.3 Solid Organ Transplantation Support 10.4 Hematopoietic Progenitor Cell Transplantation
11 Routine Serologic Testing
11.1 Blood Grouping Tests 11.2 Antibody Detection & Crossmatch 11.3 Antibody Identification & Clinical Significance 11.4 Direct Antiglobulin Testing & Reagents
12 Special Serologic Methods
12.1 Enzymes, Enhancement Media & Lectins 12.2 Adsorptions, Elutions & Titrations 12.3 Cell Separations, Neutralization & Thiol Reagents 12.4 Chloroquine Diphosphate & EDTA-Glycine Acid
13 Molecular Platforms & Serologic QA
13.1 Molecular Blood Group Techniques 13.2 ELISA, Immunofluorescence, Solid Phase & Column Agglutination 13.3 Serologic Quality Assurance
14 Indications, Component Therapy & PBM
14.1 Indications for Transfusion 14.2 Component Therapy 14.3 Blood Administration & Patient Blood Management
15 Adverse Effects of Transfusion
15.1 Immunologic Transfusion Reactions 15.2 Nonimmunologic Reactions 15.3 Transfusion-Transmitted Diseases
16 Apheresis & Extracorporeal Circulation
16.1 Therapeutic Apheresis 16.2 Extracorporeal Circulation
17 Quality, Safety, Math & Instrumentation
17.1 Quality Assessment & Troubleshooting 17.2 Laboratory Safety 17.3 Laboratory Mathematics 17.4 Instrumentation
18 Laboratory Administration (SBB Only)
18.1 Financial Management 18.2 Operations & Information Technology 18.3 Personnel, Education & Training 18.4 Quality Management, Risk & Tissue Management
13.1 Molecular Blood Group Techniques
Key Takeaways Explain This Topic AI
Weak D types 1-3 test as Rh-positive for transfusion and RhIG, while partial D is treated as Rh-negative because missing D epitopes can trigger alloanti-D
RHD genotyping is the recommended follow-up for an initial weak or discrepant D typing rather than routine serologic weak D testing alone
The RHD pseudogene (RHD-psi), common in D-negative individuals of African ancestry, can show 'RHD gene detected' without D antigen expression - not a testing error
Molecular genotyping is most valuable when autoantibodies or multiple alloantibodies prevent reliable antisera-based phenotyping
Extended RBC genotyping for chronically transfused patients should be performed before the transfusion program begins to avoid donor DNA contamination
Last updated: July 2026
13.1 Molecular Blood Group Techniques
Quick Answer: Molecular (DNA-based) blood group testing predicts antigen phenotype from an individual's genotype using PCR-based methods or SNP microarrays. On the SBB exam, molecular techniques (ASCP outline IV.C.9) are tested through classic use cases: resolving weak D discrepancies, phenotyping patients whose antibodies interfere with serologic typing, extended antigen matching for chronically transfused patients, and non-invasive fetal RHD status. Genotyping is a powerful complement to serology, not a wholesale replacement - genotype/phenotype discordance is a recurring exam trap.
Why Serology Alone Falls Short
Routine antigen typing depends on a licensed antiserum reacting visibly with antigen on an intact red cell membrane. That dependency breaks down in several everyday blood bank situations: a patient's own antibody coats the cells being tested (masking antigen sites or causing false positives with antihuman globulin-based reagents), no licensed antiserum exists for a clinically important but rare antigen, or the patient has recently received donor red cells that contaminate the sample with a mixed-field population. Molecular genotyping sidesteps each of these problems because it reads the DNA sequence encoding the blood group gene rather than the expressed protein or carbohydrate structure on the cell surface.
Genotype vs. Phenotype: The Core Relationship
A genotype is the actual DNA sequence at a blood group locus; a phenotype is the antigen profile expressed on the red cell membrane. Most of the time genotype accurately predicts phenotype, which is why genotyping panels can substitute for serologic phenotyping. But the SBB exam repeatedly tests the exceptions:
Silent (null) alleles - a gene is present but produces no detectable antigen (e.g., certain FY alleles produce the Fy(a-b-) phenotype common in people of African ancestry even though FYB sequence is present, because a promoter mutation silences erythroid expression specifically).
Hybrid/rearranged genes - unequal crossover between homologous genes (classically RHD / RHCE ) creates hybrid alleles that alter or eliminate antigen expression.
RHD pseudogene ( RHD-psi ) - present in roughly two-thirds of D-negative individuals of African ancestry; it contains RHD-like sequence and can generate a "gene detected" molecular signal even though the person is genuinely serologic D-negative because the pseudogene is not translated into functional protein. This is a classic false-alarm trap: a positive RHD gene result in this context is not a discrepancy requiring repeat serologic testing - it is an expected, well-documented finding.
Takeaway for the exam: genotyping results must always be interpreted in the context of serologic findings and known population-specific allele frequencies, never in isolation.
Platform Concepts (Know the Logic, Not Just the Brand Names)
Approach Basic Principle Typical Blood Bank Use
PCR-SSP (sequence-specific primers) Primers amplify only if they match the target allele exactly; presence/absence of a band indicates the allele Single-antigen or small panel typing (e.g., RHD exon screening)
Real-time PCR / probe-based assays Fluorescent probes detect amplification in real time, distinguishing single-nucleotide differences High-throughput screening for common SNPs (e.g., FY , JK , GYPB )
SNP microarray panels Dozens of blood group SNPs are genotyped simultaneously from one DNA sample using bead- or chip-based hybridization Extended antigen profiling for chronically transfused patients and donor rare-antigen registries
Sanger/next-generation sequencing Direct base-by-base sequence determination Resolving ambiguous or novel alleles that panel assays cannot classify
The exam cares less about specific commercial platform names than about the underlying logic: PCR-based assays interrogate known SNPs, so a novel or unlisted allele can be missed or misclassified - another reason molecular results are reported as predicted phenotype , not an absolute guarantee.
High-Yield Clinical Use Cases
1. Weak D Discrepancies. When initial Rh typing gives a weak or discrepant reaction, AABB/CAP-aligned practice calls for RHD genotyping rather than automatically performing a tube/indirect antiglobulin weak D test. Weak D types 1, 2, and 3 express a complete but quantitatively reduced D antigen and can safely be treated as Rh-positive for transfusion and RhIG purposes. Partial D , in contrast, is a qualitative change - one or more D epitopes are missing - so these patients can form alloanti-D against transfused Rh-positive cells and should be transfused with Rh-negative units and considered RhIG candidates.
2. Patients with Multiple Alloantibodies or Warm Autoantibodies. When a patient's plasma reacts with every reagent red cell (broadly reactive autoantibody) or contains several overlapping alloantibodies, serologic phenotyping with antisera becomes unreliable or impossible if the patient has been recently transfused. Genotyping determines the antigen profile directly from DNA, independent of what is happening on the cell surface serologically.
3. Chronically Transfused Patients. Patients with sickle cell disease or thalassemia who receive lifelong transfusions are at high risk of alloimmunization and benefit from extended antigen matching (Rh, K, Fya/Fyb, Jka/Jkb, S/s, and others). Genotyping should ideally be performed before the transfusion program begins, or from a source of DNA unaffected by circulating donor cells (e.g., a buccal swab or a pre-transfusion sample), because recently transfused whole blood contains donor leukocyte/DNA contamination that can distort results.
4. Fetal RHD Genotyping. Cell-free fetal DNA circulating in maternal plasma can be genotyped for RHD status non-invasively. A D-negative pregnant patient carrying a genotypically D-negative fetus does not need antenatal RhIG, avoiding unnecessary blood product exposure - an increasingly tested topic linking molecular testing to obstetric transfusion practice.
5. Platelet (HPA) Genotyping. Human platelet antigen typing by molecular methods supports workup of neonatal alloimmune thrombocytopenia (NAIT) and post-transfusion purpura , and identifies HPA-matched donors (HPA-1a is the antigen most frequently implicated in NAIT among people of European ancestry) for antigen-negative platelet support.
Section Takeaways
Genotype predicts phenotype but the two can diverge - silent alleles, hybrid genes, and pseudogenes (especially RHD-psi ) are recurring exam traps.
Weak D types 1-3 behave as Rh-positive; partial D behaves as Rh-negative for transfusion/RhIG decisions - genotyping is the tool that makes this distinction.
Genotyping is most valuable exactly when serology cannot work: interfering antibodies, recent transfusion, and prenatal fetal antigen status.
Extended molecular phenotyping should be performed before a chronic transfusion program starts whenever possible.